20 RESULTS
Go to another page:
COMMENT The increased funding for Alzheimer’s research is a very welcome and encouraging piece of news. There is little doubt that hard work from activists, researchers, editorials, and public support played their parts. Now it is up to NIH to effectively utilize
COMMENT Elenbecestat trial starts with hope and elan We were pleased to hear that elenbecestat (Eisai/Biogen) has passed Phase 2 trials with no apparent toxicity and successful changes in “pathology”—although not in actual cognitive symptoms. Several candidate BA
COMMENT A BACE1 inhibitor failure is an opportunity for selective BACE1 inhibition. Janssen recently announced that it terminated atabecestat development. The announcement further stated that serious elevations in liver enzymes were detected in some patients taki
COMMENT Merck pushing forward on clinical trials for a BACE1 inhibitor in such late stages of AD is certainly puzzling, as others have already noted. It is to be expected that, once Aβ has plateaued and sufficient Aβ-related damage has been done, there will be li
COMMENT Comment by Debomoy Lahiri and Bryan Maloney The previously proposed LEARn (Latent Early-life Associated Regulation) pathway may explain the recently featured results from Chumley and Kahn and from Knuessel et al. regarding infection and AD. Work such as t
Go to another page:
